Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab and Lenalidomide Maintenance in MRD-Positive Multiple Myeloma
NCT05344833Phase 2Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Jan 2023
- Primary completion
- Dec 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by University of Illinois Chicago. Started Jan 2023; status: recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05344833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344833.